2012
DOI: 10.3111/13696998.2012.680554
|View full text |Cite
|
Sign up to set email alerts
|

The economic impact of galantamine vs placebo: An analysis based on functional capacity in a Swedish cohort study

Abstract: The benefits of galantamine in patients with AD can be achieved with no increase in cost. Combined with positive effects in terms of outcome, treatment with galantamine can be regarded as cost-effective using a cost-consequence approach.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 41 publications
0
1
0
Order By: Relevance
“…1 ). Finally, the incremental societal cost of AChEIs remained consistent after including the study that calculated cost data as a function of activity functioning score (MD: − 2293, 95% CI [− 4983, 397]) [ 34 ].
Fig.
…”
Section: Resultsmentioning
confidence: 99%
“…1 ). Finally, the incremental societal cost of AChEIs remained consistent after including the study that calculated cost data as a function of activity functioning score (MD: − 2293, 95% CI [− 4983, 397]) [ 34 ].
Fig.
…”
Section: Resultsmentioning
confidence: 99%